Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

iFR Guided PCI to the LAD: Same as for non-LAD Vessels?

iFR has been validated as a useful tool for intermediate lesion analysis, with the advantage of not requiring the use of drugs. On the other hand, its use for PCI outcome assessment has not yet been thoroughly looked into, even though there have been promising data. 

ATC guiada por iFR ¿es igual en la descendente anterior que en el resto de los vasos?

24% of DEFINE PCI cases presented ≤0.89 iFR with a successful angiography. Those reaching ≥0.95 iFR at one year followup, showed lower incidence of cardiovascular mortality, MI, and ischemia driven revascularization. 

One analysis of the DEFINE PCI included the assessment of 506 vessels, 61.5% of the left anterior descending (LAD) and 38.5% to non-LAD vessels (99 left coronary, and 96 circumflex). It excluded cases with two vessels, which included the left main.

Primary end point at 12 months was target vessel failure, defined as a composite of cardiovascular death, MI and ischemia driven target vessel revascularization. 

There were no significant differences in bifurcation presence (4%), length (21.2 mm), stent diameter (3.0 mm) or maximum balloon pressure (18 ATM).

Read also: Can Ultrasound Treat Aortic Stenosis?

Calcified lesions in the LAD were more frequent (43.4% vs. 29.7%, p=0.002), reference vessel diameter was shorter (2.73 mm vs 2.84 mm, p<0.0001) and more post-dilation was required (63.8% vs. 51.5%, p=0.007).

Prior to PCI, LAD iFR was higher (0.82 [0.63, 0.86] vs. 0.72 [0.49, 0.84]; p<0.0001). After PCI, there were no angiographic differences in residual lesion, which was 19%.

Suboptimal iFR (<0.95) was higher in the LAD (77.8% vs 22.6%, p<0.0001). The presence of instent focal residual lesions was higher in the LAD (53.7% vs 27.3%, p=0.0009). There were no differences in primary end point at 12 months between the groups. 

In both groups, improved iFR after PCI was significantly associated with reduced angina and improved quality of life.

Read also: Revascularization vs. Deferral of Physiologically Significant Lesions in the Left Main Coronary Artery.

Independent predictors of low iFR after LAD PCI were age, larger body surface and smaller vessels; while in non-LAD lesions, predictors were calcifications and reference vessel diameter.

Conclusion

In conclusion, after PCI with successful PCI, iFR was lower in LAD lesions vs. non-LAD, which resulted in high prevalence of suboptimal iFR in the LAD. This disparity is attributed in part to a higher frequency of focal residual gradient within the stent segment, that might benefit from a more aggressive PCI.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Changes in post-PCI physiology based on anatomical vessel location: a DEFINE PCI substudy. 

Reference: Mitsuaki Matsumura, et al. EuroIntervention 2023;19-online publish-ahead-of-print November 2023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...